History of Pediatric BMT.- Stem Cell Sources and Donor Selection.- Preparative Regimens.- Graft-versus-Host Disease.- Complications Following BMT and Supportive Care.- Late Effects.- Acute Lymphoblastic Leukemia.- Acute Myeloid Leukemia.- Lymphomas.- Myelodysplastic and Myeloproliferative Disorders.- Solid Tumors.- Non-Malignant Diseases.- Future Directions.
Franklin Oscar Smith, III, gained his MD from the University of South Carolina School of Medicine, Columbia in 1984, having previously obtained a B.S. in Chemistry, cum laude, from Wofford College, Spartanburg, South Carolina. Professor Smith served as the Director of the Pediatric Stem Cell Transplantation Program at Riley Hospital for Children at the Indiana University School of Medicine from 1997 until 2001 when he appointed as the Director of the Division of Hematology/Oncology at Cincinnati Children's Hospital Medical, serving in this role until 2010. Since 2001 he has been Marjory J. Johnson Endowed Chair in Pediatric Hematology/Oncology and Professor of Pediatrics, with Tenure, at the Cincinnati Children's Hospital Medical Center, University of Cincinnati. He is also currently Interim Director of the Bone Marrow Transplantation Program and Associate Director of the Hematology/Oncology Fellowship Training Program in the Department of Internal Medicine, University of Cincinnati College of Medicine. He has been the recipient of many awards and honors, including a Distinguished Physician Alumni Award from the University of South Carolina School of Medicine, Alpha Omega Alpha membership, a Distinguished Service Award from the Children's Oncology Group, the Amanda Toll Endowed Lectureship, and the Ronald Chard Endowed Lectureship. Professor Smith was the Vice-Chair of the Children's Oncology Group, was a member of the Board of Directors of the Foundation for the Accreditation of Cellular Therapy as a member of the Medical and Scientific Affairs Committee of the Leukemia and Lymphoma Society. He has served on many National Institutes of Health and Food and Drug Administration ad hoc committees. Professor Smith has served on the editorial boards of several journals, including the British Journal of Haematology. He has authored or co-authored more than 100 peer-reviewed articles and reviews, many book chapters, editorials, and commentaries and a recent textbook on pediatric leukemia. Gregory H. Reaman, M.D., is currently Associate Director of the Office of Oncology Drug Products at the U.S. Food and Drug Administration's Center for Drug Evaluation and Research. In 2011, he completed 2 five year terms as the Chair of the Children's Oncology Group (COG) since its inception in 2000 resulting from the merger of four legacy pediatric cancer research organizations . The COG is the largest pediatric cancer research organization in the world and is comprised of over 200 member institutions throughout North America, Australia, and New Zealand , dedicated to clinical, translational, and epidemiology research in childhood cancer. Dr. Reaman is a Professor of Pediatrics at The George Washington University School of Medicine and Health Sciences and a member of the Division of Hematology-Oncology at the Children's National Medical Center in Washington, D.C., which he directed for nearly 18 years, and Executive Director Emeritus of the Center for Cancer and Blood Disorders. Dr. Reaman serves or has served on the Editorial Boards of Leukemia, Journal of Clinical Oncology, Journal of Pediatric Hematology/Oncology, Pediatric Blood and Cancer, The Oncologist, Cancer, and Physicians Data Query (PDQ), National Cancer Institute as well as the ASCO Cancer Foundation's www.cancer.net. He has served as an Associate Editor of Cancer and Leukemia and Lymphoma. Previously, he served on the Board of Directors of the American Cancer Society and chaired its Task Force on Children and Cancer. Dr. Reaman served on the Board of Directors of the American Society of Clinical Oncology and has served on the ASCO Patient Education, Education and Program, Grant Selection , the Cancer Research and Survivorship Committees and was the Chair of the ASCO Membership Committee. Also, he was a member of the Food and Drug Administration's Oncologic Drugs Advisory Committee and was a long-standing member of its Pediatric Subcommittee. He was a member of the NIH Roadmap Working Group. Additionally, he is a member of the Alliance for Childhood Cancer, a member of the Data Safety Monitoring Board of the National Cancer Institute's Clinical Oncology Program, and a member of the NCI's Translational Research Working Group. He is the author of more than 300 peer-reviewed manuscripts resulting from long-standing interests in acute leukemia biology and treatment and development of new drugs for pediatric cancer. Judy M. Racadio is a former Emergency Medicine physician who currently performs medical writing and editing for various academic medical, private medical, and corporate departments. She received her B.S. in 1988 from Xavier University in Cincinnati, Ohio (magna cum laude) and her M.D. in 1992 from the University of Cincinnati (alpha omega alpha). After completing her Emergency Medicine residency, Dr. Racadio spent 6 years as an Assistant Professor of Emergency Medicine at the University of Cincinnati. Since leaving clinical medicine, she has provided editorial assistance for a textbook on pediatric leukemia and a textbook on pediatric radiology. She has also co-authored or provided editorial assistance for more than 35 peer-reviewed publications and book chapters.